Standardizing Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer Treatment: Navigating Complexities and Charting the Path Forward

dc.contributor.author	Segura-Sampedro, Juan-José
dc.contributor.author	Cascales-Campos, Pedro-Antonio
dc.date.accessioned	2025-11-24T12:35:29Z
dc.date.available	2025-11-24T12:35:29Z
dc.date.issued	2024
dc.identifier.citation	Segura-Sampedro JJ, Cascales-Campos P. Standardizing Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer Treatment: Navigating Complexities and Charting the Path Forward. Cancers. 17 de enero de 2024;16(2):400.
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/22252
dc.description.abstract	The incorporation of hyperthermic intraperitoneal chemotherapy (HIPEC) into the treatment landscape for ovarian cancer has invoked a spectrum of emotions, ranging from enthusiastic anticipation to cautious skepticism [...].
dc.language.iso	eng
dc.publisher	Multidisciplinary Digital Publishing Institute (MDPI)
dc.rights	Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/es/	*
dc.title	Standardizing Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer Treatment: Navigating Complexities and Charting the Path Forward
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	38254889
dc.relation.publisherversion	https://www.mdpi.com/2072-6694/16/2/400
dc.identifier.doi	10.3390/cancers16020400
dc.journal.title	Cancers
dc.identifier.essn	2072-6694